Genmab, Lundbeck deal

The companies partnered to use Genmab's UltiMAb and UniBody technologies to discover and develop human antibodies against three targets selected by H. Lundbeck. Lundbeck will have an option to take selected antibodies into clinical development at its own cost for CNS indications, while Genmab will have an option for certain non-CNS indications, including cancer. ...